Form 425 - Prospectuses and communications, business combinations
18 September 2023 - 11:27PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 18, 2023
vascular
biogenics ltd.
(Exact
name of registrant as specified in its charter)
Israel |
|
001-36581 |
|
Not
Applicable |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
8
HaSatat St. |
|
|
Modi’in,
Israel |
|
7178106 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: +972-8-9935000
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☒ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Ordinary
Shares, par value NIS 0.01 each |
|
VBLT |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Information.
On
September 18, 2023, Vascular Biogenics Ltd. (“VBL”) announced that VBL shareholders may also attend the October 12, 2023
annual and special meeting of shareholders (the “Meeting”) in person at VBL’s offices at 8 HaSatat St., Modi’in,
Israel. This additional venue is in addition to the virtual format discussed in the proxy
statement/prospectus/information statement of VBL dated September 5, 2023 (the “Original
Prospectus”).
As
a result of this change, the Meeting will now be held both in:
● |
a
virtual format via live audio webcast on October 12, 2023 at 8:00 a.m., Eastern Time, and accessible via a unique access link shareholders
will receive upon registering to attend the Meeting; and |
● |
at
VBL’s offices at 8 HaSatat St. Modi’in, Israel at 3:00 p.m. Israel time (8:00 a.m. Eastern Time) on October 12, 2023. |
Additional
Information about the Proposed Merger and Where to Find It
This
communication may be deemed to be solicitation material in respect of the proposed merger transaction between VBL and Notable Labs, Inc.
(“Notable”). In connection with the proposed merger transaction, VBL has filed relevant materials with the Securities and
Exchange Commission (“SEC”), including a registration statement on Form S-4 that contains a proxy statement (the “Proxy
Statement”) and prospectus. This communication is not a substitute for the Form S-4, the Proxy Statement or for any other document
that VBL may file with the SEC and or send to VBL’s shareholders in connection with the proposed merger transaction. BEFORE MAKING
ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF VBL ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT AND OTHER DOCUMENTS FILED
WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT VBL, THE
PROPOSED MERGER TRANSACTION AND RELATED MATTERS. Investors and security holders can obtain free copies of the Form S-4, the Proxy Statement
and other documents filed by VBL with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents
filed by VBL with the SEC are also available free of charge on VBL’s website at www.vblrx.com, or by contacting VBL’s Investor
Relations at ir@vblrx.com. VBL, Notable and their respective directors and certain of their executive officers may be considered participants
in the solicitation of proxies from VBL’s shareholders with respect to the proposed merger transaction under the rules of the SEC.
Information about the directors and executive officers of VBL is set forth in its Annual Report on Form 10-K for the year ended December
31, 2022 as filed with the SEC on March 14, 2023, and in subsequent documents filed with the SEC. Additional information regarding the
persons who may be deemed participants in the proxy solicitations and a description of their direct and indirect interests, by security
holdings or otherwise, are or will be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the
SEC when they become available. You may obtain free copies of this document as described above.
No
Offer or Solicitation
This
communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor a solicitation of any vote
or approval with respect to the proposed transaction or otherwise. No offer of securities shall be made except by means of a prospectus
meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.
Forward
Looking Statements
This
communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure,
timing and completion of the proposed merger; and other statements that are not historical fact. All statements other than statements
of historical fact contained in this communication are forward-looking statements. These forward-looking statements are made as of the
date they were first issued, and were based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs
and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors
or circumstances that are beyond VBL’s control. VBL’s actual results could differ materially from those stated or implied
in forward-looking statements due to a number of factors, including but not limited to (i) the risk that the conditions to the closing
of the proposed merger are not satisfied, including the failure to timely obtain shareholder approval for the transaction, if at all;
(ii) uncertainties as to the timing of the consummation of the proposed merger and the ability of each of VBL and Notable to consummate
the proposed merger; (iii) risks related to VBL’s ability to manage its operating expenses and its expenses associated with the
proposed merger pending closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or
quasi-governmental entity necessary to consummate the proposed merger; (v) the risk that as a result of adjustments to the exchange ratio,
VBL shareholders and Notable stockholders could own more or less of the combined company than is currently anticipated; (vi) risks related
to the market price of VBL’s ordinary shares relative to the exchange ratio; (vii) unexpected costs, charges or expenses resulting
from the transaction; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion
of the proposed merger; (ix) the uncertainties associated with Notable’s platform technologies, as well as risks associated with
the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and
completion of clinical trials; (x) risks related to the inability of the combined company to obtain sufficient additional capital to
continue to advance these product candidates and its preclinical programs; (xi) uncertainties in obtaining successful clinical results
for product candidates and unexpected costs that may result therefrom; (xii) risks related to the failure to realize any value from product
candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved
in successfully bringing product candidates to market; (xiii) risks associated with the possible failure to realize certain anticipated
benefits of the proposed merger, including with respect to future financial and operating results; (xiv) risks associated with the possible
failure to receive a favorable advisory vote from VBL’s shareholders on the sale of VB-601 to Wellbeing, including closing such
sale; and (xv) risks associated with VBL’s loss of “foreign private issuer” status, among others. Actual results and
the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and
uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors
described in the section titled “Risk Factors” in VBL Annual Report on Form 10-K for the year ended December 31, 2022, as
filed with the SEC on March 14, 2023, and in other filings that VBL makes and will make with the SEC in connection with the proposed
merger, including the Proxy Statement described above under “Additional Information about the Proposed Merger and Where to Find
It.” You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of
the dates indicated in the forward-looking statements. VBL expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any such statements are based.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
VASCULAR
BIOGENICS LTD. |
|
|
|
Date: September
18, 2023 |
By: |
/s/
Dror Harats |
|
Name: |
Dror
Harats |
|
Title: |
Chief
Executive Officer |
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
Von Jun 2023 bis Jun 2024